Thomas DiRaimondo
Directeur Technique/Scientifique/R&D chez JANUX THERAPEUTICS, INC.
Fortune : 5 M $ au 30/04/2024
Profil
Thomas DiRaimondo is the founder of Sitari Pharma, Inc. (founded in 2013).
He is currently working as the Chief Scientific Officer at Janux Therapeutics, Inc. since 2018.
Dr. DiRaimondo has a doctorate degree from Stanford University and undergraduate and graduate degrees from the University of Michigan.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
JANUX THERAPEUTICS, INC.
0,20% | 02/01/2024 | 101 532 ( 0,20% ) | 5 M $ | 30/04/2024 |
Postes actifs de Thomas DiRaimondo
| Sociétés | Poste | Début |
|---|---|---|
| JANUX THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/05/2018 |
Anciens postes connus de Thomas DiRaimondo
| Sociétés | Poste | Fin |
|---|---|---|
Sitari Pharma, Inc.
 Sitari Pharma, Inc. BiotechnologyHealth Technology Sitari Pharma, Inc. provides pharmaceutical research and development services. It engages in multiple disease indications such as celiac disease. The company was founded by Chaitan S. Khosla and Thomas DiRaimondo in 2013 and is headquartered in La Jolla, CA. | Fondateur | 01/08/2019 |
Formation de Thomas DiRaimondo
| Stanford University | Doctorate Degree |
| University of Michigan | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JANUX THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Sitari Pharma, Inc.
Sitari Pharma, Inc. BiotechnologyHealth Technology Sitari Pharma, Inc. provides pharmaceutical research and development services. It engages in multiple disease indications such as celiac disease. The company was founded by Chaitan S. Khosla and Thomas DiRaimondo in 2013 and is headquartered in La Jolla, CA. | Health Technology |